hip fracture
Conditions
Interventions
Treatment Group:Voluntary grouping of patients
Control Group:Tramadol hydrochloride sustained release tablets, oral administration
Sponsors
General Hospital of Central Theater Command, PLA
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: A total of 80 elderly patients with hip fracture in our hospital from March 1, 2025 to December 31, 2026 were selected to participate in this study voluntarily and signed informed consent, age >=65 years old, regardless of gender, ASA II or III, weight 45kg ~ 86kg, and severe pain without any analgesic measures (VAS pain score >=4 points).
Exclusion criteria
Exclusion criteria: 1. More than 12 hours from the occurrence of traumatic fracture to admission; 2. Infection or bacteremia at the proposed puncture site; 3. History of relevant drug allergies and drug dependence; 4. Severe anatomical abnormalities; 5. Neurological disorders or nerve damage; 6. Coagulation abnormalities (endogenous or iatrogenic); (7) Renal insufficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma inflammatory factor levels;Serum biochemical level;Plasma immune cell levelse;sleep quality;sleep quality;Simple mental condition;Delirium grading; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chronic pain incidence;Health-related quality of life;Sufentanil dosage;Remifentanil dosage;Time of Operation;amout of bleeding;infusion quantity;urine volume;Doctor-patient satisfaction;Time of first feeding;Time of first anal exhaust;First time out of bed activity;Total hospital stay;CT imaging data; | — |
Countries
China
Contacts
Public ContactHuiying Hu
Department of Anesthesiology, General Hospital of Central Theater Command, PLA
Outcome results
None listed